Abu Dhabi Art 2025: New Beyond Emerging Artists Cohort Introduced and Global Showcase Continues
24.9.2025 16:37:00 CEST | Business Wire | Press Release
The 17th edition of Abu Dhabi Art, organised by the Department of Culture and Tourism – Abu Dhabi, will return from 19 to 23 November 2025 at Manarat Al Saadiyat. As part of its commitment to nurturing emerging talent, the fair has announced the Beyond Emerging Artists (BEA) 2025 cohort: Alla Abdunabi, Salmah Almansoori, and Maktoum Al Maktoum.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250924481559/en/
Issam Kourbaj, Courtesy Kettle’s Yard, University of Cambridge (Photo: AETOSWire)
Their new commissions will be curated by internationally renowned artist Issam Kourbaj, who will mentor them as they develop works inspired by Al Ain, a UNESCO World Heritage site.
Kourbaj commented: “Like many creatives around the world, young artists in the region are directing their gaze toward excavating the present and engaging with urgent matters of our time, whether environmental, social, or historical. I very much look forward to working with the selected artists and guiding their visual voices as they develop a body of work inspired by Al Ain, both as a source and canvas for new ideas.”
Working across installation, sculpture, and storytelling, the artists bring unique perspectives: Abdunabi explores the afterlives of objects, Almansoori reflects on disappearing spaces and memory, and Al Maktoum constructs symbolic worlds interrogating belief systems and the human psyche.
In addition to presenting at the fair, BEA artists benefit from international exposure through exhibitions abroad. As part of this outreach, works by the 2024 BEA cohort - Fatma Al Ali, Dina Nazmi Khorchid, and Simrin Mehra Agarwal - were showcased in Hong Kong and will be exhibited in London this year. Sponsored by HSBC, these global presentations extend the programme’s reach and impact.
Dyala Nusseibeh, Director of Abu Dhabi Art, said: “The BEA artists commissioned this year explore themes of heritage, capturing elusive stories of the past, examining our relationship with the world around us, and imagining possible futures through their diverse practices. The scale and ambition of the works in production are thrilling. Through this flagship programme, Abu Dhabi Art aims to give the most promising artists from our region the visibility and support they need to thrive on a global stage. The 2024 cohort’s upcoming exhibition at London’s Saatchi Gallery, supported by Friends of Abu Dhabi Art and global sponsor HSBC, highlights the power of community and partnership in championing young artists.”
For more information: www.abudhabiart.ae
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250924481559/en/
Contacts
Asma AbuBaker Aljailani
ajailani@dctabudhabi.ae
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom